Arrowhead Pharmaceuticals (ARWR) News Today $12.87 +0.53 (+4.29%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$12.87 0.00 (0.00%) As of 04/15/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Arrowhead CFO Ken Myszkowski to retire, Daniel Apel to succeedApril 15 at 11:56 PM | markets.businessinsider.comArrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial OfficerApril 15 at 6:56 PM | uk.finance.yahoo.comChristopher Richard Anzalone Sells 50,800 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) StockArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 50,800 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $11.49, for a total transaction of $583,692.00. Following the sale, the chief executive officer now owns 3,921,255 shares of the company's stock, valued at approximately $45,055,219.95. This represents a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.April 14 at 5:37 AM | marketbeat.comResona Asset Management Co. Ltd. Acquires Shares of 22,292 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Resona Asset Management Co. Ltd. bought a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 22,292 shares of the biotechnoloApril 14 at 4:12 AM | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells $406,042.54 in StockApril 12, 2025 | insidertrades.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 17.4% - Time to Buy?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Up 17.4% - Time to Buy?April 11, 2025 | marketbeat.comCenterBook Partners LP Has $6.59 Million Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)CenterBook Partners LP decreased its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 11.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 350,473 shaApril 11, 2025 | marketbeat.comTrexquant Investment LP Trims Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Trexquant Investment LP lessened its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 46.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 100,798 shares of the biotechnology company'sApril 11, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 12-Month Low - Should You Sell?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 12-Month Low - Here's What HappenedApril 9, 2025 | marketbeat.comRaymond James Financial Inc. Takes $651,000 Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Raymond James Financial Inc. purchased a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 34,633 shares of the biotechnology company's stock, vApril 8, 2025 | marketbeat.com2,054,364 Shares in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Bought by Norges BankNorges Bank acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,054,364 shares of the biotechnology company's stock, valued atApril 7, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Vanguard Group Inc.Vanguard Group Inc. reduced its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 0.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,184,289 shares of the bioApril 7, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 1-Year Low - Should You Sell?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year Low - Here's WhyApril 2, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 8% - Time to Sell?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 8% - Should You Sell?April 1, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year Low - Time to Sell?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 12-Month Low - Time to Sell?March 27, 2025 | marketbeat.comVirtu Financial LLC Makes New $381,000 Investment in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Virtu Financial LLC acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,266 shares of the biotechnologyMarch 27, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of "Moderate Buy" from BrokeragesArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has been given an average rating of "Moderate Buy" by the ten research firms that are presently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and six have given aMarch 27, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 4.8% - Time to Sell?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 4.8% - Time to Sell?March 26, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the companyMarch 25, 2025 | finance.yahoo.comHighTower Advisors LLC Cuts Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)HighTower Advisors LLC reduced its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 39.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 75,056 shares of the biotechnology compaMarch 25, 2025 | marketbeat.comIntech Investment Management LLC Has $1.67 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Intech Investment Management LLC lifted its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 160.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 88,661 shares of the biotechnology company's stock aMarch 23, 2025 | marketbeat.comArrowhead Pharmaceuticals Is Finally ArrivingMarch 21, 2025 | seekingalpha.comLeerink Partnrs Has Pessimistic View of ARWR FY2026 EarningsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities research analysts at Leerink Partnrs cut their FY2026 earnings estimates for Arrowhead Pharmaceuticals in a note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnMarch 21, 2025 | marketbeat.comPrivium Fund Management B.V. Increases Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Privium Fund Management B.V. boosted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 14.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 380,586 shares of the biotechnology companMarch 20, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 51,425 SharesArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 51,425 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the completion of the transaction, the chief executive officer now directly owns 4,062,377 shares in the company, valued at approximately $61,220,021.39. This represents a 1.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.March 18, 2025 | marketbeat.comInsider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells 51,425 Shares of StockMarch 18, 2025 | insidertrades.comWealthfront Advisers LLC Buys New Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Wealthfront Advisers LLC bought a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 109,566 shares of the biotechnology companyMarch 16, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 8.4% - Still a Buy?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 8.4% - Still a Buy?March 13, 2025 | marketbeat.comKing Luther Capital Management Corp Makes New Investment in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)King Luther Capital Management Corp bought a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 76,965 shares of the biotechnology company'sMarch 13, 2025 | marketbeat.comArrowhead Pharma Reports Positive Topline Data From Phase 1/2 Study Of ARO-C3March 12, 2025 | nasdaq.comBank of New York Mellon Corp Sells 36,341 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Bank of New York Mellon Corp lessened its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 4.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 830,058 shares of the biotechnology companMarch 12, 2025 | marketbeat.comArrowhead data supports blockbuster potential of ARO-C3, says H.C. WainwrightMarch 10, 2025 | markets.businessinsider.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 1-Year Low - Time to Sell?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 52-Week Low - What's Next?March 10, 2025 | marketbeat.comArrowhead announces topline results from ARO-C3 trialMarch 10, 2025 | markets.businessinsider.comArrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA NephropathyMarch 10, 2025 | finance.yahoo.comEdgestream Partners L.P. Makes New $2.26 Million Investment in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Edgestream Partners L.P. acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 120,411 shares oMarch 10, 2025 | marketbeat.comArrowhead presents data on candidates to treat obesity, metabolic diseasesMarch 6, 2025 | markets.businessinsider.comChristopher Richard Anzalone Sells 133,333 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) StockArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 133,333 shares of the firm's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total value of $2,269,327.66. Following the sale, the chief executive officer now owns 3,773,802 shares in the company, valued at $64,230,110.04. This trade represents a 3.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.March 6, 2025 | marketbeat.comArrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic DiseasesMarch 6, 2025 | businesswire.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells $2,269,327.66 in StockMarch 6, 2025 | insidertrades.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Holdings Increased by Fisher Asset Management LLCFisher Asset Management LLC increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 16.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 142,939 shares of the biotechnology company's stock after puMarch 6, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 1-Year Low - Here's WhyArrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 52-Week Low - Should You Sell?March 5, 2025 | marketbeat.comPinion Investment Advisors LLC Makes New Investment in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Pinion Investment Advisors LLC acquired a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 75,March 4, 2025 | marketbeat.comInteresting ARWR Call Options For April 17thFebruary 26, 2025 | nasdaq.comArrowhead presents preclinical results on ARO-ALK7February 25, 2025 | markets.businessinsider.comArrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of ObesityFebruary 25, 2025 | businesswire.comState of New Jersey Common Pension Fund D Increases Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)State of New Jersey Common Pension Fund D lifted its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 40.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor ownedFebruary 23, 2025 | marketbeat.comEmpowered Funds LLC Takes $268,000 Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Empowered Funds LLC acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,273 shares of the biotechnology comFebruary 22, 2025 | marketbeat.comArrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy NowFebruary 20, 2025 | insidermonkey.comArrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy NowFebruary 20, 2025 | msn.com Remove Ads Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address ARWR Media Mentions By Week ARWR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARWR News Sentiment▼0.740.79▲Average Medical News Sentiment ARWR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARWR Articles This Week▼126▲ARWR Articles Average Week Remove Ads Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BridgeBio Pharma News TG Therapeutics News Legend Biotech News Telix Pharmaceuticals Limited American Depositary Shares News Blueprint Medicines News Sarepta Therapeutics News Axsome Therapeutics News Nuvalent News ADMA Biologics News Grifols News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARWR) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
